Advanced search
Publication Cover
Pharmacogenomics Volume 10, 2009 - Issue 12
Submit an article Journal homepage
658
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Genetic Determinants of Warfarin Dosing in the Han-Chinese Population

MT Michael Lee1 Institute of Biomedical Sciences, Academia Sinica, 128, Academia Road, Section 2, NanKang, Taipei, Taiwan. ;2 China Medical University, Taichung, TaiwanView further author information
,
Chien-Hsiun Chen1 Institute of Biomedical Sciences, Academia Sinica, 128, Academia Road, Section 2, NanKang, Taipei, Taiwan. ;2 China Medical University, Taichung, TaiwanView further author information
,
Ching-Heng Chou1 Institute of Biomedical Sciences, Academia Sinica, 128, Academia Road, Section 2, NanKang, Taipei, Taiwan. View further author information
,
Liang-Suei Lu1 Institute of Biomedical Sciences, Academia Sinica, 128, Academia Road, Section 2, NanKang, Taipei, Taiwan. View further author information
,
Hui-Ping Chuang1 Institute of Biomedical Sciences, Academia Sinica, 128, Academia Road, Section 2, NanKang, Taipei, Taiwan. View further author information
,
Ying-Ting Chen1 Institute of Biomedical Sciences, Academia Sinica, 128, Academia Road, Section 2, NanKang, Taipei, Taiwan. View further author information
,
Amir N Saleem1 Institute of Biomedical Sciences, Academia Sinica, 128, Academia Road, Section 2, NanKang, Taipei, Taiwan. ;3 College of Veterinary Medicine, University of Mosul, IraqView further author information
,
Ming-Shien Wen4 Chang Gung University College of Medicine, Chang Gung Memorial Hospital, Taoyuan, TaiwanView further author information
,
Jin-Jer Chen1 Institute of Biomedical Sciences, Academia Sinica, 128, Academia Road, Section 2, NanKang, Taipei, Taiwan. ;5 National Taiwan University Hospital, Taipei, TaiwanView further author information
,
Jer-Yuarn Wu1 Institute of Biomedical Sciences, Academia Sinica, 128, Academia Road, Section 2, NanKang, Taipei, Taiwan. ;2 China Medical University, Taichung, TaiwanView further author information
&
Yuan-Tsong Chen1 Institute of Biomedical Sciences, Academia Sinica, 128, Academia Road, Section 2, NanKang, Taipei, Taiwan. ;6 Duke University Medical Center, Durham, NC, USACorrespondence[email protected]
View further author information
 show all
Pages 1905-1913 | Published online: 03 Dec 2009

Bibliography

  • Hirsh J : Antithrombotic therapy in deep vein thrombosis and pulmonary embolism.Am. Heart J.123 , 1115–1122 (1992).
  • Hirsh J , DalenJ, AndersonDR et al.: Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.Chest119 , S8–S21 (2001).
  • Laupacis A , AlbersG, DalenJ, DunnM, FeinbergW, JacobsonA: Antithrombotic therapy in atrial fibrillation.Chest108 , S352–S359 (1995).
  • Stein PD , AlpertJS, CopelandJ, DalenJE, GoldmanS, TurpieAG: Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves.Chest108 , S371–S379 (1995).
  • Loebstein R , YonathH, PelegD et al.: Interindividual variability in sensitivity to warfarin – nature or nurture?Clin. Pharmacol. Ther.70 , 159–164 (2001).
  • Takahashi H , WilkinsonGR, CaracoY et al.: Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients.Clin. Pharmacol. Ther.73 , 253–263 (2003).
  • Zhao F , LokeC, RankinSC et al.: Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose.Clin. Pharmacol. Ther.76 , 210–219 (2004).
  • Bogousslavsky J , RegliF: Anticoagulant-induced intracerebral bleeding in brain ischemia. Evaluation in 200 patients with TIAs, emboli from the heart, and progressing stroke.Acta Neurol. Scand.71 , 464–471 (1985).
  • Gullov AL , KoefoedBG, PetersenP: Bleeding complications to long-term oral anticoagulant therapy.J. Thromb. Thrombolysis1 , 17–25 (1994).
  • Landefeld CS , BeythRJ: Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention.Am. J. Med.95 , 315–328 (1993).
  • Miners JO , BirkettDJ: Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.Br. J. Clin. Pharmacol.45 , 525–538 (1998).
  • Rettie AE , KorzekwaKR, KunzeKL et al.: Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions.Chem. Res. Toxicol.5 , 54–59 (1992).
  • Takahashi H , EchizenH: Pharmacogenetics of warfarin elimination and its clinical implications.Clin. Pharmacokinet.40 , 587–603 (2001).
  • Furuya H , Fernandez-SalgueroP, GregoryW et al.: Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy.Pharmacogenetics5 , 389–392 (1995).
  • Nasu K , KubotaT, IshizakiT: Genetic analysis of CYP2C9 polymorphism in a Japanese population.Pharmacogenetics7 , 405–409 (1997).
  • Xie HG , PrasadHC, KimRB, SteinCM: CYP2C9 allelic variants: ethnic distribution and functional significance.Adv. Drug Deliv. Rev.54 , 1257–1270 (2002).
  • Ngow HA , Wan Khairina WM, Teh LK et al.: CYP2C9 polymorphism: prevalence in healthy and warfarin-treated Malay and Chinese in Malaysia. Singapore Med. J.50 , 490–493 (2009).
  • Bell RG , MatschinerJT: Warfarin and the inhibition of vitamin K activity by an oxide metabolite.Nature237 , 32–33 (1972).
  • Wallin R , MartinLF: Vitamin K-dependent carboxylation and vitamin K metabolism in liver. Effects of warfarin.J. Clin. Invest.76 , 1879–1884 (1985).
  • D‘Andrea G , D‘AmbrosioRL, Di Perna Pet al.: A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood105 , 645–649 (2005).
  • Rieder MJ , ReinerAP, GageBF et al.: Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.N. Engl. J. Med.352 , 2285–2293 (2005).
  • Wadelius M , ChenLY, DownesK et al.: Common VKORC1 and GGCXpolymorphisms associated with warfarin dose.Pharmacogenomics J.5 , 262–270 (2005).
  • Yuan HY , ChenJJ, LeeMT et al.: A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.Hum. Mol. Genet.14 , 1745–1751 (2005).
  • Wen MS , LeeM, ChenJJ et al.: Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes.Clin. Pharmacol. Ther.84 , 83–89 (2008).
  • Wu AH , WangP, SmithA et al.: Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations.Pharmacogenomics9 , 169–178 (2008).
  • Gage BF , EbyC, JohnsonJA et al.: Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin.Clin. Pharmacol. Ther.84 , 326–331 (2008).
  • Cain D , HutsonSM, WallinR: Assembly of the warfarin-sensitive vitamin K 2,3-epoxide reductase enzyme complex in the endoplasmic reticulum membrane.J. Biol. Chem.272 , 29068–29075 (1997).
  • Loebstein R , VecslerM, KurnikD et al.: Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9.Clin. Pharmacol. Ther.77 , 365–372 (2005).
  • Wajih N , SaneDC, HutsonSM, WallinR: The inhibitory effect of calumenin on the vitamin K-dependent γ-carboxylation system. Characterization of the system in normal and warfarin-resistant rats.J. Biol. Chem.279 , 25276–25283 (2004).
  • Presnell SR , StaffordDW: The vitamin K-dependent carboxylase.Thromb. Haemost.87 , 937–946 (2002).
  • Cha PC , MushirodaT, TakahashiA et al.: High-resolution SNP and haplotype maps of the human γ-glutamyl carboxylase gene (GGCX) and association study between polymorphisms in GGCX and the warfarin maintenance dose requirement of the Japanese population.J. Hum. Genet.52 , 856–864 (2007).
  • Lin PJ , JinDY, TieJK, PresnellSR, StraightDL, StaffordDW: The putative vitamin K-dependent γ-glutamyl carboxylase internal propeptide appears to be the propeptide binding site.J. Biol. Chem.277 , 28584–28591 (2002).
  • Presnell SR , TripathyA, LentzBR, JinDY, StaffordDW: A novel fluorescence assay to study propeptide interaction with γ-glutamyl carboxylase.Biochemistry40 , 11723–11733 (2001).
  • Rieder MJ , ReinerAP, RettieAE: γ-glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose.J. Thromb. Haemost.5 , 2227–2234 (2007).
  • Kimura R , MiyashitaK, KokuboY et al.: Genotypes of vitamin K epoxide reductase, γ-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.Thromb. Res.120 , 181–186 (2007).
  • Chen LY , ErikssonN, GwilliamR, BentleyD, DeloukasP, WadeliusM: γ-glutamyl carboxylase (GGCX) microsatellite and warfarin dosing.Blood106 , 3673–3674 (2005).
  • Shikata E , IeiriI, IshiguroS et al.: Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and γ-glutamyl carboxylase) gene variants with warfarin sensitivity.Blood103 , 2630–2635 (2004).
  • Saupe J , ShearerMJ, KohlmeierM: Phylloquinone transport and its influence on γ-carboxyglutamate residues of osteocalcin in patients on maintenance hemodialysis.Am. J. Clin. Nutr.58 , 204–208 (1993).
  • Berkner KL , RungeKW: The physiology of vitamin K nutriture and vitamin K-dependent protein function in atherosclerosis.J. Thromb. Haemost.2 , 2118–2132 (2004).
  • Wadelius M , ChenLY, ErikssonN et al.: Association of warfarin dose with genes involved in its action and metabolism.Hum. Genet.121 , 23–34 (2007).
  • Lal S , SandanarajE, JadaSR et al.: Influence of APOE genotypes and VKORC1 haplotypes on warfarin dose requirements in Asian patients.Br. J. Clin. Pharmacol.65 , 260–264 (2008).
  • Otagiri M , MaruyamaT, ImaiT, SuenagaA, ImamuraY: A comparative study of the interaction of warfarin with human α 1-acid glycoprotein and human albumin.J. Pharm. Pharmacol.39 , 416–420 (1987).
  • Caldwell MD , AwadT, JohnsonJA et al.: CYP4F2 genetic variant alters required warfarin dose.Blood111 , 4106–4112 (2008).
  • Takeuchi F , McGinnisR, BourgeoisS et al.: A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose.PLoS Genet.5 , E1000433 (2009).
  • Tsai MF , LinYJ, ChengYC et al.: PrimerZ: streamlined primer design for promoters, exons and human SNPs.Nucleic Acids Res.35 , W63–W65 (2007).
  • Loebstein R , DvoskinI, HalkinH et al.: A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance.Blood109 , 2477–2480 (2007).
  • Watala C , GolanskiJ, KardasP: Multivariate relationships between international normalized ratio and vitamin K-dependent coagulation-derived parameters in normal healthy donors and oral anticoagulant therapy patients.Thromb. J.1 , 7 (2003).
  • Yoshizawa M , HayashiH, TashiroY et al.: Effect of VKORC1 -1639 G>A polymorphism, body weight, age, and serum albumin alterations on warfarin response in Japanese patients.Thromb. Res.124 , 161–166 (2009).
  • Cooper GM , JohnsonJA, LangaeeTY et al.: A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose.Blood112 , 1022–1027 (2008).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.